What does “10 million cells, 90% viable” mean?

Suppose a clinic gives you those two numbers. Before you compare them with another offer, look for the unit next to the count. Does it say 10 million cells in the whole vial, or 10 million per millilitre? Then look for the word viable. Some labs have already excluded cells that failed their viability test. [1] [3]

Here is a worked example. A 2 mL vial contains 5 million total cells per mL. That gives an estimated 10 million total cells in the vial. If 90% of the cells counted in a representative sample from that vial pass the viability test, the estimate is 9 million viable cells. Both measurements need to describe the same cell population at the same stage of preparation.

If the report already says 9 million viable cells per vial, use that figure as written. Multiplying it by 90% again would count the same loss twice. This arithmetic helps you read a label. Choosing a dose takes clinical evidence for the preparation and condition being treated.

How did the lab decide which cells were viable?

One common test uses a blue dye. A cell with an intact outer membrane keeps the dye out. When the membrane is damaged, the dye can enter. The lab uses that difference to classify the cells it can see. [2]

In a 2022 experiment using a human cell line called Jurkat, researchers showed that how dark a stained cell appeared could vary with the microscope settings. They measured how much light the dye absorbed to make results easier to compare across instruments. Their experiment tells you something practical about two viability percentages side by side. You also need the method each lab used. [2]

When was the sample tested?

Some mesenchymal stromal cell (MSC) preparations are used fresh. Others are frozen, stored and thawed. If the product was frozen, ask whether the result on the report came from before freezing or after thawing. How much time passed between preparation and testing? Was the tested sample handled the same way as the cells the clinic plans to use? [3]

François and colleagues tested human bone marrow MSCs in the lab. Just after thawing, the cells were less able to slow the multiplication of activated T cells, one kind of immune cell. After 24 hours back in culture, that activity recovered under the conditions tested. Two ways of measuring viability also gave different estimates. The researchers measured immune activity in a dish. How a patient would respond, or how a different product should be handled, would take separate evidence. [4]

An expert group that developed reporting guidelines for MSC studies recommended including the viability method and result before administration. For frozen preparations, they also asked researchers to report whether cells were used straight after thawing or put back into culture. Look for those details when comparing the clinic's product with one described in a paper. [3]

What else belongs beside the count?

A certificate of analysis is a lab report for a particular batch. Health Canada’s guidance for cell therapy trials and the European Medicines Agency’s human cell product guideline describe several distinct measurements. Three questions can help you read the rest of the report. [1] [6]

  • Which cells are in the sample? Identity testing checks for characteristics expected of the intended cells. If the preparation contains a mixture, ask what fraction of the count belongs to the cell population you are discussing.
  • What can these cells do? Potency testing measures biological activity relevant to the product's intended effect. Ask which function was measured and how it relates to the proposed treatment.
  • What contamination checks were performed? Ask which tests have final results for this batch, including the sterility test. With a short-lived product, some results can still be pending. Find out which ones and when they will be available.

The FDA’s November 2026 guidance for cell and gene therapy manufacturers describes how production controls and testing work together to preserve potency. It asks manufacturers to consider what happens after a batch leaves the lab, including storage, shipping and preparation. If a report gives a viability percentage, ask to see the separate evidence for the activity the manufacturer expects those cells to perform. [5]

For example, one 2026 lab study compared eight batches of fat-derived MSCs and nine batches of bone marrow MSCs. The researchers mixed the cells with activated immune cells and measured how much the T cells multiplied. Both sources slowed T cell multiplication. Which source appeared more active depended on the immune response measured. The experiment tested what those batches could do in the dish. [7]

Can viability be linked to what happens to patients?

One clinic looked back at 93 men treated for erectile dysfunction related to blood flow. They received an injection of a mix of cells from their own fat tissue along with medication for erectile dysfunction. The clinic used trypan blue to test each preparation before the injection. At six months, 66 men met the study's threshold for erection hardness. The average viability in their preparations was 88%, compared with 82.5% in the other 27 men's preparations. [8]

The men who met the threshold were also younger on average and less likely to have diabetes. Everyone received the injection. The clinic did not assign preparations by viability, and the researchers used the same group to derive and assess a proposed viability cutoff. The association is worth testing in a new group. These records alone cannot tell a patient whether raising the viability of a preparation would improve their outcome. [8]

Which report applies to the treatment being proposed?

Bring the report to your clinician and start with the product name and lot number. Once you know which batch the results cover, ask to see a study of that preparation in people with your condition. What did researchers measure in those people, what were the results and how long did they follow up? Our guide to reading a study walks through those questions using actual trials.

Questions people ask

Does 95% viability mean I have a 95% chance of improving?

No. With a cell-counting test, it means the lab classified about 95 out of every 100 cells it counted as viable. To estimate the chance of improvement, look for studies in people with your condition who received the same preparation.

Does a larger cell count make one product better?

A larger figure can refer to a different volume or a different mix of cells. Ask which cells were counted, whether the number already excludes dead cells and what clinical evidence supports the proposed dose.

What does it mean if the report says a batch passed?

Ask which tests the batch passed, what limits the manufacturer used and whether any results are pending. To check authorization, ask the treating team which regulatory pathway applies to that product and use in the country where treatment would take place.

Sources and further reading

Sources checked November 10, 2026. Sources include three laboratory experiments, one retrospective patient study, an expert reporting consensus and guidance from three regulators. The patient study assessed one preparation for one condition.

US GUIDANCE5. U.S. Food and Drug Administration. Potency Assurance for Cellular and Gene Therapy Products. Final guidance for industry, November 2026.
EU GUIDANCE6. European Medicines Agency. Guideline on Human Cell-Based Medicinal Products. Effective 2008. Sections 4.2.3 through 4.2.5.

This article is educational and is not personal medical advice. A qualified treating clinician should assess your condition and discuss suitable options, expected benefits and risks. Any treatment decision should be made with a qualified physician. Individual results vary.